Aims To determine the extent and time-course of hepatic and intestinal cytochrome P450 3A (CYP3A) inactivation due to the mechanism-based inhibitor clarithromycin. Methods Intestinal and hepatic CYP3A inhibition was examined in 12 healthy volunteers following the administration of single and multiple doses of oral clarithromycin (500 mg). Intestinal biopsies were obtained under intravenous midazolam sedation at baseline and after the first dose, on days 2-4, and on days 6-8 of the clarithromycin treatment. The formation of 1′-hydroxymidazolam in biopsy tissue and the serum 1′-hydroxymidazolam:midazolam ratio were indicators of intestinal and hepatic CYP3A activity, respectively. Results Intestinal CYP3A activity decreased by 64 % (p0 0.0029) following the first dose of clarithromycin, but hepatic CYP3A activity did not significantly decrease. Repeated dosing of clarithromycin caused a significant decrease in hepatic CYP3A activity (p00.005), while intestinal activity showed little further decline. The CYP3A5 or CYP3A4*1B genotype were unable to account for inter-individual variability in CYP3A activity.
tissue inhibitor concentrations were too low to cause significant competitive inhibition, consistent with the hypothesis that clarithromycin likely causes irreversible inhibition of intestinal CYP3A activity [9] .
Recently, we proposed a semi-physiological pharmacokinetic model that describes the pharmacokinetic interaction between clarithromycin and midazolam [10] . This model incorporates the hepatic and intestinal metabolism of clarithromycin and midazolam and mechanism-based inactivation of intestinal and hepatic CYP3A by clarithromycin. The model accurately predicted the extent of the interaction at steady-state dosing, based on the fold-change in the intravenous (IV) and oral area under the time-concentration curve (AUC) of midazolam. In addition, the recovery of intestinal and hepatic CYP3A was consistent with the observed fold-change in the oral and IV midazolam AUC at 1, 36, 72, and 144 h after discontinuation of clarithromycin dosing (500 mg every 12 h for 7 days). This interaction model indicates that a single dose of clarithromycin produces near-maximal CYP3A inactivation in the intestine but that hepatic CYP3A requires several doses before maximum inactivation occurs. However, no data on the onset of CYP3A inactivation by clarithromycin were available to validate this finding. Thus, this study was designed to elucidate the timing and extent of CYP3A inhibition in the liver and intestine during treatment with clarithromycin, using midazolam as a probe substrate. The effect of the CYP3A5 genotype on hepatic and intestinal CYP3A activity before and after inhibition was also investigated.
Materials and methods

Subjects
The study was performed in 12 healthy subjects (6 men, 6 women), aged ≥18 years, who had consumed no prescription or over-the-counter medications for at least 2 weeks before the study. Individuals with an intolerance to macrolide antibiotics or benzodiazepines or a significant medical history of smoking or alcohol intake were excluded from the study. Subjects were excluded from participating in the study if the blood tests revealed a low platelet cell count (<100,000/mL) or a high international normalized ratio (>1.5). For at least 2 weeks prior to the start of the study until its conclusion, volunteers were restricted from consuming any food or beverage containing grapefruit or grapefruit juice, vegetables from the mustard green family (kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard, etc) and charbroiled meats. Additionally, food or beverage items containing xanthenes (e.g. coffee, tea, chocolate, colas) were not consumed by the subjects 48 h prior to beginning of the baseline phase and throughout the study. The Clarian and Indiana University Purdue University Indianapolis (IUPUI) Institutional Review Board approved this study. All subjects provided written informed consent.
Study design
Each volunteer underwent four endoscopies prior to and during a weekly course of oral clarithromycin 500 mg twice daily (Biaxin XL®; Abbot Laboratories, Abbot Park, IL). The first (baseline) endoscopy was performed within 1 week (day −7 to day −1) prior to the subject starting clarithromycin treatment. Three additional endoscopies were performed 12 h after the first dose and on days 2-4 and 6-8 of clarithromycin treatment (Fig. 1) . Following an overnight fast, individuals were dosed with IV midazolam (Roche Pharmaceuticals, Nutley, NJ) to achieve effective conscious sedation (Table 1) for the esophagogastroduodenoscopy (EGD). Mucosal biopsy specimens were obtained from the second portion of the duodenum and were immediately snap frozen in liquid nitrogen and stored at −80°C until analysis. During each endoscopy visit, blood samples were obtained prior to and 1, 2, and 3 h after midazolam administration. Compliance with clarithromycin dosing and diet, alcohol, and drug restrictions was assessed by pill count and subject interviews.
Duodenal homogenates
Small bowel biopsy specimens (approximately 20 μg wet tissue weight) were homogenized as described previously [9] . Duodenal biopsy specimens were homogenized by a hand-held glass homogenizer in 1 mL ice-cold buffer consisting of 50 mmol/L Tris(hydroxymethyl) aminomethane, 2 mmol/L ethylenediaminetetraacetic acid, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L benzamidine, 50 μg aprotinin, and 20 % glycerol (pH 7.4). The resultant homogenate was immediately snap frozen in liquid nitrogen and stored at −80°C until assayed. Homogenate protein concentrations were determined by the method of Lowry et al. [11] using bovine serum albumin as the standard. 
Immunoblotting
An aliquot (15 μg) of small-bowel homogenate was mixed with 5× nonreducing sample buffer (Pierce, Rockford, IL) and heated to 95°C for 5 min. The samples were electrophoresed in 9 % polyacrylamide/0.1 % sodium dodecyl sulfate gels using a Bio-Rad Protean II Unit (Bio-Rad, Hercules, CA) and then transferred onto a Hybond-P hydrophobic polyvinylidene difluoride membrane (Amersham Pharmacia Biotech, Piscataway, NJ) with 25 mmol/L Tris and 192 mmol/L glycine buffer at 100 V for 1.5 h. The blots were first blocked for 1 h in Tris-buffered saline containing 5 % nonfat dry milk, and the membrane was then incubated overnight with a 1:500 dilution of polyclonal antibody to CYP3A4 (Gentest, Woburn, MA) or with villin antibody (Thermo Scientific, Rockford, IL) in Tris buffered saline. After extensive washing with Tris-buffered saline solution containing 0.1 % Tween 20, the membranes were probed with a horseradish peroxidase secondary antibody and developed with an enhanced chemifluorescence kit (GE Healthcare, Piscataway, NJ). The membrane was exposed to BioMax Light 2 film (Kodak, Rochester, NY), and optical densities of the bands on the film were converted to quantitative numbers using the Kodak Electrophoresis Documentation and Analysis System 290 (EDAS 290) and Kodak onedimensional image analysis software (Kodak, Rochester, NY). The amount of CYP3A4 in the biopsy specimens was obtained by comparison with serial dilutions of recombinant human CYP3A4 (Gentest). The standards were run on the same gel as the biopsy samples. The concentrations of CYP3A4 in the enterocytes were expressed relative to the concentration of the enterocyte-specific protein villin in the same sample.
Midazolam hydroxylation activity
An aliquot of 0.5 mL of small-bowel homogenate was diluted with 0.5 mL of 100 mmol/L sodium phosphate buffer (pH 7.4) and incubated at 37°C with 5 or 50 μmol/L midazolam. The reaction was initiated with the addition of 1 μmol NADPH and was quenched after 10 min with 1 mL of ethyl acetate/ hexane (50:50, v/v) and then with 1 mL of 1 N sodium hydroxide/1-mol/L glycine (pH 11.3) buffer on ice; N-desmethyldiazepam was added to the mixture as an internal standard. The mixture was then extracted with an additional 3 mL of ethyl acetate/hexane (50:50, v/v). The organic phase was dried under vacuum, and samples were reconstituted in 100 μL of mobile phase and analyzed by liquid chromatography/ mass spectrometry (LC/MS) as described below.
Midazolam and clarithromycin assays
Midazolam and 1′-hydroxymidazolam were quantified using desmethyldiazepam as the internal standard, as previously described in detail [12] . Compounds of interest were separated by use of a Luna C18 column (5 μm, 4.6×150-mm internal diameter; Phenomenex, Torrance, CA) equipped with a Brownlee RP-18 guard column (Perkin Elmer, Shelton, CT). 200°C and 550°C, respectively. N-desmethyldiazepam, midazolam, and 1′-hydroxymidazolam were detected with selected ion monitoring at mass-to-charge ratios of 271, 326, and 342, respectively. The limit of quantification in serum was 0.25 ng/mL for midazolam and 1′-hydroxymidazolam; the respective corresponding coefficient of variation and relative error for midazolam and 1′-hydroxymidazolam at 1.4, 10, and 40 ng/mL were less than 7 and 10 %. Serum clarithromycin, 14-hydroxyclarithromycin, and Ndesmethylclarithromycin concentrations were determined using troleandomycin as the internal standard, as previously described in detail [13] . In brief, the compounds of interest were separated by passage through a C8 column (5 μm, 100 × 4.6-mm internal diameter; Brownlee, Perkin Elmer) and a mobile phase of 20 mmol/L ammonium acetate, pH 7/ methanol (20:80, v/v). The mobile phase was delivered isocratically at 1 mL/min. Detection was achieved by use of a mass spectrometer with an APCI inlet (Navigator; Finnigan, San Jose, CA). The limits of quantitation were 2.5 ng/mL for clarithromycin and its metabolites. The respective corresponding coefficients of variation and relative error for clarithromycin and its metabolites at 10 ng/mL were less than 8 and 9 %.
CYP3A5 genotype
Genomic DNA was extracted from whole blood by use of the Qiagen Midi kit according to the manufacturer's instructions (Qiagen, Valencia, CA). Genotyping of CYP3A5*3, CYP3A5*6, CYP3A5*7, and CYP3A4*1B was carried out using a previously described method [14, 15] ; the PCR cycling conditions were: 5 min at 95°C; 35 cycles of 0.5 min at 94°C, 0.5 min at 55°C, and 1 min at 72°C, followed by a final 10-min cycle at 72°C. CYP3A5 high expressers were defined as having at least one CYP3A5*1 allele. CYP3A5 low expressers were defined as having two variant alleles, CYP3A5*3, *6, or *7, that result in reduced protein expression or the expression of proteins with greatly reduced activity.
Intestinal and hepatic CYP3A activities Intestinal CYP3A activity was determined by the ex vivo formation of 1′-hydroxymidazolam in homogenized biopsy tissue. V max (maximum reaction rate) and K m (concentration of substrate that gives half-maximal activity) were obtained from the double-reciprocal plot of the data and the ex vivo CL int (intrinsic clearance) was calculated as V max /K m . The ratio of serum 1′-hydroxymidazolam to midazolam obtained 3 h after the midazolam dose was used as an in vivo indicator of hepatic CYP3A activity based on previous data [16] .
Statistical analysis
Data are reported as mean and standard deviation (SD). Recruitment of 12 subjects provided 83 % power to detect a twofold change in formation rates of 1′-hydroxymidazolam, with 5 % type I error. Changes in hepatic and intestinal activity from baseline and the effect of CYP3A5 genotype were compared by analysis of variance (ANOVA) and the Wilcoxon test with the Bonferroni correction for multiple comparisons. All statistical analyses were performed using R statistical software [17] .
Results
The 12 subjects completed the study without adverse effects. The subject demographics and the doses of clarithromycin and midazolam administered prior to each endoscopy are shown in Table 1 . One subject (subject #12) received three doses of clarithromycin prior to the second endoscopy; thus only the data from 11 subjects was included for the 12-h time-point analysis. The third and fourth endoscopies were performed as per protocol except that one subject (subject #12) received a total of 15 doses of oral clarithromycin prior to the last endoscopy.
CYP3A4 and CYP3A5 genotype
Four individuals were CYP3A5 high expressers: two homozygous and two heterozygous (Table 1) . CYP3A4*1B was expressed by five individuals, including the four CYP3A5 high expressers and subject 3 who carried the CYP3A5*6 allele.
Intestinal CYP3A activity and expression A reduction in intestinal CYP3A activity was observed for all individuals after the first dose of clarithromycin (Fig. 2) . With the exception of one subject, intestinal activity remained suppressed throughout the course of treatment. Mean intestinal CYP3A activity decreased by 64 % from 0.22 pmol min -1 mg -1 [95 % confidence interval (CI) 0.13-0.31] to 0.10 pmol min -1 mg -1 (95 % CI 0.05-0.14) following the first dose of clarithromycin (p00.0029; Fig. 3 ). The mean intestinal CYP3A activity further decreased to 0.06 pmol min -1 mg -1 (95 % CI 0.03-0.08) and 0.08 pmol min -1 mg -1 (95 % CI 0.01-0.15) by the third and fourth endoscopies, respectively (Fig. 3) . CYP3A4 protein from ten of the 12 volunteers was quantified by Western blot and normalized to villin expression. A large variability in expression was noted (Fig. 4) , but there was no difference between the endoscopies in amount of CYP3A4 protein expressed (p00.92).
Hepatic CYP3A activity Hepatic CYP3A activity, as assessed by the 3-h 1'-hydroxymidazolam:midazolam serum ratio, was less rapidly inhibited by clarithromycin than intestinal CYP3A activity. As shown in Fig. 2 , there was a greater variability in hepatic CYP3A activity than in intestinal CYP3A activity following the first dose of clarithromycin, with three individuals showing increased clearance of midazolam. With the exception of one individual, hepatic activity was suppressed after 1 week of treatment with clarithromycin (Fig. 2) . The mean hepatic 1′-hydroxymidazolam:midazolam ratio after the first dose of oral clarithromycin was not significantly different from baseline, i.e., 0.22 (95 % CI 0.17-0.27) and 0.19 (95 % CI 0.14-0.24), respectively (p 0 0.92; Fig. 3) . A significant decrease in hepatic CYP3A activity was seen with subsequent doses of clarithromycin. Hepatic CYP3A activity decreased by 42 (p0 0.0088), and 48 % (p00.07) from baseline by the third and fourth endoscopies, respectively (Fig. 3) . When the three individuals for whom hepatic activity increased by >1.1-fold following the first dose of clarithromycin does were excluded, the decrease in hepatic activity between the first and second EGD remained non-significant following the first dose of clarithromycin (71±26 % of baseline; p00.2) 
Clarithromcyin concentration
Clarithromycin and 14-hydroxyclarithromycin were detected in all plasma samples, with mean clarithromycin concentrations of 13.3±9.4, 22.1±12.4, and 27.8±13.5 μM and mean 14-hydroxyclarithromcyin concentrations of 3.12 ±1.25, 4.47±2.27, and 4.18±1.52 μM at endoscopies 2, 3, and 4, respectively. The clarithromcyin plasma concentration was weakly but statistically associated with hepatic CYP3A activity (r 2 00.13, p00.03), but was not associated with intestinal CYP3A activity (p00.44).
CYP3A5 genotype and inhibition of intestinal CYP3A activity
There was no significant (p00.37) difference in the baseline intestinal CYP3A activity between CYP3A5 high expressers (n04) and low expressers (n08). When stratified by their CYP3A5 genotype, the decrease in intestinal CYP3A activity with the first dose of oral clarithromycin was not significant for CYP3A5 high expressers (p00.55), but it was significant for CYP3A5 low expressers (p00.046; Fig. 5 ). There was no significant difference between the high expressers and low expressers in terms of the extent of intestinal CYP3A inhibition at the time of the fourth endoscopy (p>0.99).
CYP3A5 genotype and inhibition of hepatic CYP3A activity There was no significant (p00.81) difference in the baseline hepatic CYP3A activity between CYP3A5 high expressers and low expressers. When stratified by their CYP3A5 genotype, the decrease in the hepatic CYP3A activity with the first dose of oral clarithromycin was not significant for either the CYP3A5 low expressers or high expressers (Fig. 5) . CYP3A5 low expressers showed a significant drop in hepatic CYP3A activity from the baseline by the third endoscopy (p00.046), whereas hepatic activity did not significantly decrease by the third endoscopy in CYP3A5 high expressers (p00.94). There was no significant difference between the high expressers and low expressers in terms of the extent to which hepatic CYP3A was inhibited at the time of the fourth endoscopy (p00.68).
Discussion
The accurate prediction of drug-drug interactions involving mechanism-based inactivators requires a knowledge of drug-specific properties, such as the K I (inhibitor concentration for half-maximal inactivation) and k inact (maximal inactivation rate constant), as well as the enzyme-specific half-life. These properties, combined with the pharmacokinetic profile of the inactivator, determine the extent of the drugdrug interaction. By evaluating the change in 1′-hydroxymidazolam formation during treatment with clarithromycin, we demonstrated a differential effect of inactivation on intestinal and hepatic CYP3A. Twelve hours after a single dose of clarithromycin, the intestinal CYP3A activity was reduced by 64 %, indicating significant inactivation of CYP3A in the gut wall. However, several doses of clarithromycin were required before maximum inactivation of hepatic CYP3A was achieved.
Midazolam is a selective CYP3A probe both in vitro and in vivo [1, 18] , and its disposition is not dependent on the activity of the p-glycoprotein efflux transporter (MDR1) [19, 20] . Midazolam is metabolized by CYP3A to form 1′-hydroxymidazolam and a minor metabolite, 4-hydroxymidazolam in vitro and in vivo in humans [18, 21] ; less than 1 % of the midazolam dose is excreted unchanged in the urine following IV administration. In this study, midazolam was administered IV at a dose required for sedation (5-10 mg), and the ratio of 1′-hydroxymidazolam to midazolam concentration in plasma was used to assess hepatic CYP3A activity, as previously described [9, 16] . Midazolam is efficiently extracted by intestinal CYP3A, with up to 75 % of the first-pass loss of midazolam following oral administration occurring in the intestinal wall [1, 22] . Thus, we also used midazolam as an ex vivo measure of CYP3A activity in intestinal biopsy samples, as previously described [9] . The average plasma concentration of 1′-hydroxymidazolam observed 2-3 hours after midazolam administration was 0.14-0.16 ng/mL. Thus, any 1′-hydroxymidazolam present in the homogenate would be negligible and not impact the observed in vitro clearance of midazolam. Therefore, we do not expect residual in vivo metabolites of midazolam to have confounded the estimation of 1′-hydroxymidazolam formation rate. Additionally, we have shown previously [8] that the residual concentration of clarithromycin in the homogenates is minimal and lower than its competitive inhibition rate constant (K I ) for CYP3A.
The quantification of hepatic CYP3A activity was obtained from the single-point plasma measurement of the ratio of 1′-hydroxymidazolam to midazolam at 3 h after IV midazolam dosing. The single point ratio of 1′-hydroxymidazolam:midazolam has been used extensively as a measure of CYP3A activity [23] [24] [25] [26] [27] [28] [29] . In particular, this ratio is strongly correlated with hepatic CYP3A4 content (r 2 00.87) [30] and with midazolam clearance (r 2 00.89) [31] . Inter-individual variability in CYP3A activity may occur due to the presence of CYP3A4 or CYP3A5 polymorphisms [32] . The rate of 1′-hydroxymidazolam formation is twofold greater for CYP3A5 than for CYP3A4 [18, 33] , and differential inhibition kinetics of CYP3A4 and CYP3A5 have been reported [34] [35] [36] . The catalytic activity of CYP3A5 has been shown to be less susceptible than CYP3A4 to time-dependent inhibition by erythromycin and verapamil, and CYP3A5 has also been found to have a slower maximum rate of enzyme inactivation than CYP3A4 in vitro [37, 38] . Both CYP3A4 and CYP3A5 contribute to the total CYP3A activity in vivo and, therefore, the time-course and maximal inhibitory effect was postulated to be different in CYP3A5 high expressers compared to low expressers. However, the four CYP3A5 high expressers in our study did not differ from CYP3A5 low expressers in either baseline activity or extent of inactivation of intestinal or hepatic CYP3A activities after 7 days of treatment with clarithromycin. Statistically significant reductions were observed in intestinal activity in CYP3A5 low expressers-but not high expressers-after the first dose of clarithromycin. It should be noted, however, that this study was not powered to detect a difference between genotypes, and the linkage disequilibrium noted between CYP3A4*1B and CYP3A5*1 makes it impossible to distinguish between the two genotypes without a large sample size.
The results of this study are consistent with those previously evaluating the turn-over rate of CYP3A enzyme. Halflife estimates for CYP3A4 range from 20 to 85 h [39] [40] [41] [42] . Greenblatt et al. estimated the turnover rate of intestinal CYP3A to be 23 h based on the time-course of recovery of intestinal CYP3A following single doses of grapefruit juice [39] . Okudaira et al. found that the AUC of oral midazolam increased by 2.32-and 3.38-fold following 2 and 4 days of erythromycin 200 mg four times daily. They estimated the turnover of CYP3A as 22.8 h [42] . As in our study, Okudaira et al. found a large inter-individual variability in the extent of CYP3A inhibition by erythromycin. However, they did not account for CYP3A5 genotype, nor were they able to separately examine intestinal and hepatic CYP3A activity.
Bartkowski et al. examined the effect of erythromycin on the clearance of IV alfentanil [43] . Similar to our findings, no effect was observed following the first dose of erythromycin (500 mg), but the systemic clearance of alfentanil was increased by 1.6-fold following a 7-day course of erythromycin [43] . Compared to erythromycin, clarithromycin is a more potent CYP3A mechanism-based inhibitor, with the in vitro K I estimated to be between 4 and 31 mg/L and with a k inact of 2.5-4.3 in human liver microsomes [5, 44] . In the present Fig. 6 Simulated effect of clarithromycin on hepatic and intestinal CYP3A activity. A semi-physiologically based pharmacokinetic model incorporating effects of clarithromycin inactivation in the intestine and liver was developed. Clarithromycin 500 mg was administered orally every 12 h. a, b Simulated hepatic and gut-wall concentrations of clarithromycin. c Predicted (line) and observed (box plot/point estimates) hepatic CYP3A activity. d Predicted (line) and observed (box plot/point estimates) gut-wall CYP3A activity study, hepatic CYP3A exhibited a 50 % reduction in activity following 7 days of clarithromycin.
The results of this study are consistent with a model we have developed for the inactivation of intestinal and hepatic CYP3A by clarithromycin [10] . The semi-physiologically based pharmacokinetic model incorporates intestinal and hepatic inactivation of CYP3A by clarithromycin. This CYP3A inactivation directly reduces the clearance of both clarithromycin and midazolam, and the intestinal activity appears to be well-predicted by the model. However, the extent of inactivation of hepatic CYP3A is slightly overestimated compared to that observed in this study. As shown by this model (Fig. 6) , intestinal CYP3A is exposed to a higher concentration of clarithromycin (Fig. 6b) than is hepatic CYP3A (Fig. 6a) following the first dose of inhibitor. We postulate that this high concentration of clarithromycin in the intestines results in a rapid inactivation of CYP3A (Fig. 6d) , reaching a near maximal extent following a single dose. However, the presence of this high concentration of clarithromycin in the gut wall is short-lived, with no detectable clarithromycin present 12 h after dosing [9] . Thus, intestinal CYP3A activity begins to recover within the 12-h dosing interval. On the other hand, the concentration of clarithromycin in the liver following the initial dose is lower than that in the gastrointestinal tract. However, unlike the gastrointestinal tract where new enterocytes are produced, the inhibitor may accumulate in the hepatocytes upon subsequent dosing. Therefore, less CYP3A inactivation occurs following each dose of clarithromycin, but the enzyme does not have time to recover before the next dose (Fig. 6c) . This results in an additional inactivation with each dose until a steady-state is reached.
The timing of the inhibition of intestinal CYP3A is critical to understanding when a patient taking an oral concomitant CYP3A substrate is at risk of experiencing a drugdrug interaction. This timing will be dependent on not only the properties of the inhibitor, but also on those of the substrate drug. The bioavailability of CYP3A substrates with high gut-wall extraction (i.e., low gut-wall availability) will be increased following a single dose of clarithromycin. These drugs, such as simvastatin, atorvastatin, and buspirone, are also characterized by substantial increases in oral exposure following inhibition of gut-wall CYP3A by grapefruit juice [45] [46] [47] . However, CYP3A substrates with higher gut-wall availability, such as alprazolam, nifedipine and quinidine, are not dependent on gut-wall CYP3A, and the inhibitory effects of clarithromycin will mirror the hepatic inactivation of CYP3A and will be delayed, only appearing after multiple doses of inhibitor. Similarly, the absorption properties of the inhibitor may affect the time-course of intestinal inactivation. Clarithromycin was administered as a slow-release formulation (Biaxin XL®), which may have increased its contact time with gut-wall CYP3A, thereby delaying enzyme recovery. Gut-wall enzyme recovery may begin sooner following the administration of a mechanismbased inhibitor with a faster absorption rate and reduced intestinal residence time.
In conclusion, the onset of intestinal CYP3A inhibition occurs following the first dose of the mechanism-based CYP3A inhibitor clarithromycin. In contrast, reduction in hepatic CYP3A activity is delayed, and several doses of clarithromycin are required to reach the nadir. Although the inter-individual variability in CYP3A baseline activity and the rate of inactivation were both high, these findings could not be explained by CYP3A genotype.
